Decision

Teva Canada Innovation v. Pharmascience Inc., 2019 FC 595 (Glatiramer*)

Proth. Tabib - 2019-05-07

Read full decision. Automatically generated summary:

In the context of this action, filed pursuant to section 6(1) of the recently amended Patented Medicines (Notice of Compliance) Regulations SOR/93-133 (“the Regulations”), the Defendant Pharmascience Inc. seeks to strike out portions of the Statement of Claim of the Plaintiffs Teva Canada Innovation and Teva Canada Limited (collectively referred to as “Teva” in these reasons) on the basis that they improperly plead or join a cause of action in infringement in respect of a drug product for which Pharmascience already holds a Notice of Compliance and which has not been addressed in a Notice of Allegation.

Decision relates to:

  • T-2182-18 - TEVA CANADA INNOVATION ET AL. v. PHARMASCIENCE ET AL.

 

Canadian Intellectual Property